



DuPont Pharmaceuticals Company

9141 '00 MAY 31 A9:28  
May 30, 2000

**VIA FEDERAL EXPRESS**

Dockets Management Branch (HFA-305)  
Food and Drug Administration  
5630 Fishers Lane, Room 1061  
Rockville, Maryland 20852

**RE: INTERNATIONAL CONFERENCE ON HARMONISATION; E11**  
**CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS IN THE PEDIATRIC**  
**POPULATION**  
**REQUEST FOR COMMENTS (DOCKET NO. 00D-1223)**

Dear Sir or Madam,

Reference is made to the above-referenced draft guidance. Notice of availability of this draft guidance, as well as request for comment, was published in the April 12, 2000, edition of the FEDERAL REGISTER.

In response to this request for comments, attached is feedback from the DuPont Pharmaceuticals Co. on the content of the draft guidance.

We appreciate the opportunity to comment on this draft guidance.

Sincerely,

Jamie Warner  
Associate Director  
Regulatory Affairs

Submitted in Duplicate

00D-1223

C 2

## **DOCKET NO. 00D-1223**

### **INTERNATIONAL CONFERENCE ON HARMONISATION; E11 CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS IN THE PEDIATRIC POPULATION**

#### **COMMENTS ON DRAFT GUIDANCE**

##### **SECTION 2.3 TIMING OF STUDIES**

Section 2.3 discusses the timing of studies. While it is understandable to start pediatric trials early in Section 2.3.1 (Diseases Predominantly/Exclusively Affecting Pediatric Patients) and Section 2.3.2 (Serious/Life-Threatening Diseases--once reasonable evidence of potential benefit exists), we do not fully agree with the proposal in Section 2.3.3 (Medicinal Products Intended to Treat Other Diseases and Conditions). It states that testing in these populations would not usually begin until Phase 2 or 3. There is minimal discussion around risk benefit considerations. We believe that if the product does not address a clear medical need as in Sections 2.3.1 and 2.3.2, there should be a risk benefit analysis, addressing the incidence of the disease in pediatrics, the outcome of the disease, the alternatives available to treat the disease and the risks of exposing pediatrics to a novel product without a clearly-defined safety and efficacy profile in any population. The difficulty in recruiting patients into this type of study needs to be considered. The last line of this paragraph mentions risk-benefit; however, we believe that the risk-benefit is the most important consideration in starting studies in pediatric patients where there is not a clear unmet medical need.

##### **SECTION 2.4.3 SAFETY**

This section discusses safety and gaining a better understanding of the long-term effects of drugs in the pediatric population. While we agree that this is needed especially in drugs intended to treat pediatric diseases, it would seem valuable for the guidance document to discuss some other approaches that could be used versus "long term studies" for the category of drugs discussed in Section 2.3.3 (Medicinal Products Intended to Treat Other Diseases and Conditions).

##### **GENERAL COMMENT**

We believe that this guidance document should be revised to include other ways in which to collect pediatric data outside the well-controlled trial, i.e., discuss expanded access programs to gain exposure to new medicines especially when these products are approved in adult populations.


# FedEx USA Airbill

FedEx  
Tracking  
Number

806958868123

0210

I.D. No.

SPH22  
FedEx Retrieval Copy**1 From**Date 5/30/00 Sender's FedEx Account Number 1607-2570-2Sender's Name Jamie Warner Phone (302) 852-0819Company DUPONT PHARMACEUTICAL COAddress 974 CENTRE RD Chestnut Run Plaza, Maple Run 2144City WILMINGTON State DE ZIP 19805**2 Your Internal Billing Reference Information****3 To**Recipient's Name Food and Drug Administration Phone ( )Company Dockets Management Branch (HFA-305)Address 5630 Fishers Lane, Rm. 1061 Dept./Floor/Suite/Room City Rockville State MD ZIP 20852**For HOLD at FedEx Location check here**☐ **Hold Weekday** ☐ **Hold Saturday**  
(Not available at all locations)  
(Available for FedEx Priority Overnight and FedEx 2Day only)**For WEEKEND Delivery check here**☐ **Saturday Delivery** ☐ **NEW Sunday Delivery**  
(Available for FedEx Priority Overnight and FedEx 2Day only)  
(Available for FedEx Priority Overnight only)

8 0 6 9 5 8 8 6 8 1 2 3

**4a Express Package Service Packages under 150 lbs.**

Delivery commitment may be later in some areas

☒ **FedEx Priority Overnight** (Next business morning)  
☐ **FedEx Standard Overnight** (Next business afternoon)  
☐ **FedEx First Overnight** (Earliest next business morning delivery to select locations) (Higher rates apply)  
☐ **FedEx 2Day** (Second business day)  
☐ **FedEx Express Saver** (Third business day)  
FedEx Letter Rate not available. Minimum charge: One pound rate.**4b Express Freight Service Packages over 150 lbs.**

Delivery commitment may be later in some areas

☐ **FedEx Overnight Freight** (Next business day)  
☐ **FedEx 2Day Freight** (Second business day)  
☐ **FedEx Express Saver Freight** (Up to 3 business days)

(Call for delivery schedule. See back for detailed descriptions of freight services.)

**5 Packaging** ☒ **FedEx Letter** ☐ **FedEx Pak** ☐ **FedEx Box** ☐ **FedEx Tube** ☐ **Other Pkg.**  
Declared value limit \$500**6 Special Handling**Does this shipment contain dangerous goods? ☒ **No** ☐ **Yes** (Shopper's Declaration not required)  
☐ **Dry Ice** (Dry Ice, 9, UN 1845) \* ☐ **Cargo Aircraft Only**  
\*Dangerous Goods cannot be shipped in FedEx packaging.**7 Payment**Bill to: ☒ **Sender** ☐ **Recipient** ☐ **Third Party** ☐ **Credit Card** ☐ **Cash/Check**  
(Enter FedEx Account No. or Credit Card No. below)FedEx Account No. 1607-2570-2Credit Card No.  Exp. Date Total Packages 1 Total Weight 10.3 Total Charges 

\*When declaring value higher than \$500 per shipment, you pay an additional charge. See SERVICE CONDITIONS, DECLARED VALUE, AND LIMIT OF LIABILITY section for further information.

**8 Release Signature**

Signature authorizes Federal Express to deliver this shipment without obtaining a signature and agrees to indemnify and hold harmless Federal Express from any resulting claims.

321

WCSL 0590  
Rev. Date 3/96  
Part #153023  
34 3811011  
PRINTED IN U.S.A.

006067482 5